Track RemeGen Co., Ltd. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

RemeGen Co., Ltd. 9995.HK Open RemeGen Co., Ltd. in new tab

115.20 HKD
P/E
64.49
EPS
1.46
P/B
19.80
ROE
32.91
Beta
0.72
Target Price
101.18 HKD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateApril 27, 2026
P/E64.49
EPS1.46
Book Value4.76
Price to Book19.80
Debt/Equity94.09
% Insiders10.576%
Growth
Revenue Growth2.01%
Estimates
Forward P/E66.58
Forward EPS1.41
Target Mean Price101.18

DCF Valuation

Tweak assumptions to recompute fair value for RemeGen Co., Ltd. (9995.HK)
Currency: HKD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

RemeGen Co., Ltd. Logo RemeGen Co., Ltd. Analysis (9995.HK)

China Health Care Official Website Stock

Is RemeGen Co., Ltd. a good investment? RemeGen Co., Ltd. (9995.HK) is currently trading at 115.20 HKD. Market analysts have a consensus price target of 101.18 HKD. This suggests the asset is currently trading above analyst expectations.

In terms of valuation, the stock trades at a P/E ratio of 64.49. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: RemeGen Co., Ltd. is expected to release its next earnings report on April 27, 2026. The market consensus estimate for Forward EPS is 1.41.

Investor FAQ

Does RemeGen Co., Ltd. pay a dividend?

No, it does not currently pay a dividend.

What asset class is RemeGen Co., Ltd.?

RemeGen Co., Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be April 27, 2026. The company currently has a trailing EPS of 1.46.

Company Profile

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.

Exchange Ticker
HKG (Hong Kong) 9995.HK

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion